| Chronic Kidney Disease |
1 |
1 |
| Heart Failure (HF) |
0 |
0.92 |
| Heart |
0 |
0.78 |
| Cardiovascular Risk Management |
0 |
0.66 |
| Type 2 Diabetes Mellitus |
0 |
0.9 |
| Renal Failure |
0 |
0.52 |
| Cardiovascular Imaging |
0 |
0.51 |
| Hospital |
0 |
0.39 |
| Renal Disease |
0 |
0.39 |
| Cardiovascular disease |
0 |
0.29 |
| Hyperkalemia |
0 |
0.19 |
| Nucleoside Reverse Transcriptase Inhibitors |
0 |
0.15 |
| Outpatient Clinic |
0 |
0.15 |
| GLP-1 Receptor Agonist |
0 |
0.13 |
| Antiretroviral Therapy for HIV Infection |
0 |
0.11 |
| End-Stage Renal Disease |
0 |
0.11 |
| Health Care Reform |
0 |
0.11 |
| HIV Infection |
0 |
0.11 |
| Ejection Fraction |
0 |
0.1 |
| Receptors |
0 |
0.1 |
| Brachial |
0 |
0.05 |
| California |
0 |
0.05 |
| Cost-Benefit Analysis |
0 |
0.05 |
| Europe |
0 |
0.05 |
| Indiana |
0 |
0.05 |
| Michigan |
0 |
0.05 |
| Travel Medicine |
0 |
0.05 |
| Cerebrovascular Accident |
0 |
0.04 |